Panbela Therapeutics Inc. (PBLA)
(Delayed Data from OTC)
$0.41 USD
-0.03 (-6.82%)
Updated Apr 26, 2024 03:27 PM ET
2-Buy of 5 2
F Value B Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Panbela Therapeutics Inc. [PBLA]
Reports for Purchase
Showing records 61 - 73 ( 73 total )
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology-Looking into 1Q22, Cash Balance, & Price Target Changes
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Longer Duration of Survival Observed in Phase I Pancreatic Cancer Trial
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- Catalysts from Our Coverage Universe: YE2021 and Beyond
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
3Q21: Initiation of Two Clinical Trials by YE2021
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
"Consider Reading" Vol 21: Polyamine Inhibition Promotes T-cell Viability in Animals & Implications for PBLA
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
We are initiating with a Buy rating and $10 PT.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T